Fate Therapeutics has appointed Laura Hamill, a seasoned biopharma commercial leader, to its Board of Directors as it advances its cell therapy pipeline toward later-stage clinical development and commercialization. Hamill brings over 30 years of experience, including leadership roles at Gilead Sciences and Amgen, where she managed large commercial operations and product launches. Her expertise is expected to support Fate's transition to a commercial-stage company and help deliver innovative off-the-shelf cell therapies for cancer and autoimmune diseases to patients globally. This move signals Fate's commitment to scaling its business and preparing for market entry of its novel therapies.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
